Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 19/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | HTR3A | P46098 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5995588 | 1.00 | SLC6A9 (1.00) | SLC6A9CYP1A2CYP3A4HTR1ACYP2D6 | |
| SCHEMBL5996602 | 0.90 | SLC6A9 (1.00) | SLC6A9 | |
| SCHEMBL5996606 | 0.90 | SLC6A9 (1.00) | SLC6A9 | |
| SCHEMBL5997337 | 0.90 | SLC6A9 (1.00) | SLC6A9HTR1AHTR3A | |
| SCHEMBL5997331 | 0.90 | SLC6A9 (1.00) | SLC6A9HTR1AHTR3A | |
| SCHEMBL5996788 | 0.88 | SLC6A9 (0.82) | SLC6A9HTR1AHTR3A | |
| SCHEMBL5997366 | 0.88 | SLC6A9 (0.82) | SLC6A9 | |
| SCHEMBL5996794 | 0.88 | SLC6A9 (0.82) | SLC6A9HTR1AHTR3A | |
| SCHEMBL5997370 | 0.88 | SLC6A9 (0.82) | SLC6A9 | |
| SCHEMBL1689512 | 0.88 | SLC6A9 (1.00) | SLC6A9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060223857-A1 | Combination of a serotonin reuptake inhibitor and a glycine transporter type 1 inhibitor for the treatment of depression | H. LUNDBECK A/S (DK) | 2006-10-05 | — | — | US | claimed |
| US-20060223857-A1 | Combination of a serotonin reuptake inhibitor and a glycine transporter type 1 inhibitor for the treatment of depression | H. LUNDBECK A/S (DK) | 2006-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223857-A1 | Combination of a serotonin reuptake inhibitor and a glycine transporter type 1 inhibitor for the treatment of depression | SLC6A4, SLC6A7, SLC6A5 | SLC6A9 14/4885CYP1A2 799/4885CYP3A4 833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.